首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 製藥企業 > 確保市場關係:補貼、與付費者之間的關係、醫療改革
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

確保市場關係:補貼、與付費者之間的關係、醫療改革

Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform

出版商 Cutting Edge Information
出版日期 2009年07月 商品編碼 94401
內容資訊 英文 90 Pages
價格
US $ 7695 PDF by E-mail (Single User License)
US $ 23995 PDF by E-mail (Multi User License)


確保市場關係:補貼、與付費者之間的關係、醫療改革 是由出版商Cutting Edge Information在2009年07月所出版的。 這份英文市場調查報告書包含90 Pages 價格從美金7695起跳。

簡介

本報告書內容包括:促進補貼過程進步及因應付費者需求的企業策略調整分析。內容綱要摘記如下:

封面圖片:
表紙

實施概要

  • 調查方法
  • 介紹的企業
  • 付費者關係管理:成功5大原則

透過溝通加強關係

  • 發展更有效介面的策略
  • 以經管理照護服務的消費者為目標
  • 溝通策略及戰術

經管理的市場結構、人員安排、預算

  • 概要
  • 人員安排
  • 預算

醫療改革及對經管理市場團隊造成的影響

  • 美國醫療制度改革的影響
  • 歐洲醫療制度對市場關係策略造成的影響

目錄

Abstract

Strengthen payer relationships through communication:

Of all factors contributing to product success, payer access could be the most critical. Without the best reimbursement status for a drug, the investments your company made during drug development may end up as a lost cause. Securing Market Access: Reimbursement, Payer Relationships and Healthcare Reform examines the processes, strategies and best practices that industry leaders have implemented to build strong relationships and gain payer access.

This report is a tool for companies to adjust their strategies to meet growing payer demands and facilitate the reimbursement process:

Improve payer communication and formulary submission success.

Metrics on payer targeting, communication methods and timing guide the strategic recommendations leading to healthier and more lucrative relationships for pharmaceutical companies with payers.

Increase the efficiency of your managed market department:

Analyze benchmarking data from surveyed companies on organizational structure, headcount distribution for various functions within the managed markets group, account distribution and resource allocation.

Understand the impact of potential healthcare reform on managed markets teams

Although there are no clear-cut solutions to healthcare reform, this report provides recommendations for drug companies to prepare for both minor and major changes to the healthcare system. Interviewed pharmaceutical executives discuss their strategic responses to potential changes that could be on the managed markets horizon. Cutting Edge Information' s analysts designed the practices contained within to help managed markets teams develop strategies to respond effectively to various scenarios that could emerge.

Table of Contents

Metrics Overview

Securing Market Access' three chapters include structure, budget, staffing and key performance metrics data collected from 20 top pharmaceutical and biotechnology companies.

Strengthening Payer Relationships through Communication

Percentage of all companies specific targeting managed care institutions, by type of account:

  • Commercial managed care (MCOs)
  • Medicare/Medicaid (federal and state)
  • Long-term care
  • Industry/trade
  • Federal markets (DoD, VHA)

Percentage of companies targeting managed care groups, by portfolio type:

  • Primary care (companies that develop and/or market a majority of primary care products)
  • Specialty (develop and/or market a majority of specialty products)
  • Product-Balanced (manage a relatively even-split between primary-care and specialty products)
  • Ranking of importance for managed care institutions
  • Ranking of importance for managed care institutions, by portfolio type (primary care, specialty, and product-balanced)
  • Development phase during which companies initially contact payers
  • Number of contacts with payers during each phase of development
  • Payer interfaced per phase by portfolio type (primary care, specialty, and product-balanced)
  • Percentage of companies' preferred methods of communication with payers, by phase: email, telephone, face-to-face
  • Year after drug approval that communication with payers stops

Managed Markets Structure, Staffing and Budgets

  • Percentage of companies with formal managed markets departments
  • Departments in which managed markets groups typically reside
  • Average staff size of a managed markets department (in FTEs)
  • Average staffing allocation of a managed markets department' s personnel
  • Average managed markets FTE allocation by portfolio type (primary care, specialty, and product-balanced)
  • Average FTEs per product ratios by portfolio type (primary care, specialty, and product-balanced)
  • FTEs and FTE-to-product ratios by portfolio type (primary care, specialty, and product-balanced)
  • Account manager FTEs by product focus and type of account
  • Account manager per product by company and type of manager (regional account managers or national account managers)
  • Percentage of companies that organize account managers by geography, by portfolio type (primary care, specialty, and product-balanced)
  • Average budget for a managed markets department
  • Average budget allocation for a managed markets department
  • Average budget per product ratios by portfolio type (primary care, specialty, and product-balanced)
  • Budgets by portfolio type: primary care-product-focused (as well as specialty-focused and balanced) companies - also per product
  • Managed markets marketing budget allocation by portfolio type (primary care, specialty, and product-balanced)
  • Managed markets sales manager budget allocation by portfolio type (primary care, specialty, and product-balanced)
  • Managed markets account manager budget allocation by portfolio type (primary care, specialty, and product-balanced)
  • Managed markets administrative budget allocation by portfolio type (primary care, specialty, and product-balanced)

Healthcare Reform and its Impact on Managed Markets Teams

  • Cost ranges for comparative effectiveness research
  • NICE' s probability of Rejection vs. Cost per QALY

Additional Data

  • Percentage breakdown of all healthcare spending by payers
  • Average costs for pharmacoeconomic research
Back to Top